Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01937676
NCT01937676CompletedNot Applicable

LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting

Karolinska Institutet1 site in 1 country1,250 target enrollmentStarted: September 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
1,250
Locations
1
Primary Endpoint
Development of multiple organ failure
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is evaluate if K3, a novel biomarker, sampled at arrival to the emergency department can be used to predict the development of organ failure measured as SOFA score. K3 consists of lactate dehydrogenase, albumin and magnesium combined.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age ≥18 years
  • •Admitted to emergency department, Karlstad Central Hospital, Sweden

Exclusion Criteria

  • •Not in need of venous blood sample

Outcomes

Primary Outcomes

Development of multiple organ failure

Time Frame: 30 days or complete ICU stay

Measured as SOFA score.

Secondary Outcomes

  • All cause mortality(30 days after admission to emergency department)
  • Cardiac function(30 days or complete ICU stay)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Fredrik Helliksson

MD

Karolinska Institutet

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
A pilot assessment of the feasibility of a notification system for patients with high-risk laboratory abnormalities in acute surgical wards
ACTRN12615000146594Austin Health205
Active, not recruiting
Not Applicable
Development of Novel Biomarkers for the Early Diagnosis of Type 1 DiabetesType 1 Diabetes
NCT04164966AdventHealth Translational Research Institute28
Recruiting
Not Applicable
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung CancerAdenocarcinoma of LungNode Lung
NCT05665504H. Lee Moffitt Cancer Center and Research Institute250
Recruiting
Not Applicable
Investigation of biomarkers for diagnosis and treatment of pulmonary hypertension.Pulmonary hypertension
JPRN-UMIN000032888Juntendo University50
Unknown
Not Applicable
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneHormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast Cancer
NCT02109913Amsterdam UMC, location VUmc175